Closely-held CellAegis Devices entered into a definitive agreement with Cardiologic, for the marketing and distribution of its autoRIC device in the UK and Ireland.
“This marks the first distribution agreement for the autoRIC device outside of Canada and is a significant step forward for our international commercialization strategy,” Rocky Ganske, CEO of CellAegis, said in a statement.
“Cardiologic’s strong track record of success launching innovative medical devices and novel technologies in the UK and Ireland, combined with its focus on improving both the treatment and the standard of care for cardiology and cardiac surgery patients, makes them an ideal partner for CellAegis as we work to introduce autoRIC to clinicians in Europe,” he added.
The autoRIC device automatically delivers remote ischemic conditioning to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures. The technology is CE Marked and Health Canada approved, and is currently limited to investigational use in the U.S.
Martyn Dixon, managing director of Cardiologic, said the distribution agreement for the UK and Ireland will give the company an opportunity to enhance its offering in interventional cardiology, addressing the very significant costs caused by ischemic and reperfusion injuries. These are exciting times.”
